SHANGHAI – Astrazeneca plc, of London, has invested continuously in China’s R&D capabilities over the past seven years and shows no signs of letting up. The latest deal with the newly minted Nephrology and Urology Center, part of the Shenzhen University Health Science Center, will focus on preclinical research for diabetic nephropathy, the damage done to kidneys in late-stage diabetes.